PulseAugur
EN
LIVE 15:00:06

New Bayesian detector finds cancer resistance in ctDNA below detection limits

By PulseAugur Editorial · [2 sources] ·

Researchers have developed a new Bayesian change-point detector called Span, designed to analyze serial circulating-tumour DNA (ctDNA) data. This method treats non-detects as left-censored observations, enabling the detection of drug resistance earlier than traditional methods. In simulations for metastatic breast cancer, Span approximately doubled the detection rate of impending progressions three months in advance compared to snapshot analyses. AI

IMPACT This new statistical method could improve early detection of drug resistance in cancer patients by leveraging intermittent ctDNA signals.

RANK_REASON The cluster contains a research paper detailing a new statistical method.

Read on arXiv cs.LG →

AI-generated summary · Google Gemini · from 2 sources. How we write summaries →

COVERAGE [2]

  1. arXiv cs.LG TIER_1 English(EN) · Aarchi Singh Thakur, Abhijoy Sarkar ·

    Seeing Below the Limit of Detection: A Censored-Poisson Bayesian Latent-Growth Change-Point Detector (the Span Detector) for Serial ctDNA in HR+/HER2- Metastatic Breast Cancer

    arXiv:2606.11876v1 Announce Type: cross Abstract: Circulating-tumour DNA (ctDNA) carries evidence of drug resistance months before imaging shows it, but the earliest evidence lives below the assay's limit of detection (LoD): a nascent subclone is detected only intermittently, pro…

  2. arXiv cs.LG TIER_1 English(EN) · Abhijoy Sarkar ·

    Seeing Below the Limit of Detection: A Censored-Poisson Bayesian Latent-Growth Change-Point Detector (the Span Detector) for Serial ctDNA in HR+/HER2- Metastatic Breast Cancer

    Circulating-tumour DNA (ctDNA) carries evidence of drug resistance months before imaging shows it, but the earliest evidence lives below the assay's limit of detection (LoD): a nascent subclone is detected only intermittently, producing a flickering sequence of faint detects and …

RELATED TOPICS